The global genetic testing market plays a pivotal role in personalized medicine, wherein individuals' DNA is analyzed to tailor treatments and medications based on their genetic profile. By identifying mutations and variations in DNA, healthcare providers can optimize therapeutic strategies, particularly in areas like cancer treatment, where genetic testing informs drug response. Additionally, genetic testing enables early detection and prevention of inherited disorders, empowering individuals to make proactive healthcare decisions. This approach enhances precision in healthcare interventions, offering targeted solutions that maximize efficacy while minimizing adverse effects.
The Global Genetic Testing Market valued at USD 1,84,50,983 thousand in 2023is projected to reach USD 6,26,07,580.19 thousand by 2031, and will grow at a CAGR of 16.5% during the forecast period of 2024-2031.
Below are the Top Genetic Testing Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Illumina, Inc.
|
Illumina is a leading provider of genetic sequencing and array-based solutions, offering a range of products for genetic testing applications. Their technology enables high-throughput sequencing and analysis of DNA, facilitating research and clinical diagnostics in areas such as oncology, reproductive health, and rare diseases.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In August 2021, Illumina Inc. announced that it acquired GRAIL to accelerate patient access to cancer early-detection tests. This will help the company to increase its product portfolio.
|
|
2.
|
Cepheid
|
Cepheid specializes in molecular diagnostics, offering rapid and accurate testing solutions for infectious diseases, genetic conditions, and healthcare-associated infections. Their GeneXpert platform provides automated testing capabilities, streamlining workflows and enhancing efficiency in genetic testing laboratories.
|
|
America, Asia-Pacific, and Europe
|
In October 2021, Cepheid announced the launch of direct commercial operations in Canada. Cepheid Canada's operations will include direct service, order management, and technical support. This will strengthen its footprint in Canada and help in overall development of the company.
|
|
3.
|
Fulgent Genetics
|
Fulgent Genetics is known for its comprehensive genetic testing services, providing panels and tests for a wide range of genetic disorders and conditions. They leverage advanced sequencing technologies to deliver accurate and timely results, catering to both clinical and research needs in the genetic testing market.
|
|
North America
|
In May 2022, Fulgent Genetics announced the opening of its new state-of-the-art oncology laboratory in El Monte, California, near the Company’s global headquarters in Temple City. This new CLIA-certified lab will enable Fulgent to expand its capabilities in somatic molecular diagnostics and cancer testing and more efficiently serve oncology clients on the West Coast of the United States. This acquisition helped to generate more revenue and boosted the market growth.
|
|
4.
|
PerkinElmer Inc.
|
PerkinElmer offers a diverse portfolio of products and services for genetic testing, including reagents, instruments, and software solutions. Their offerings span various applications, from prenatal screening and newborn screening to oncology and pharmacogenomics, supporting healthcare providers and researchers in their genetic testing endeavors.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In December, PerkinElmer, Inc. announced the research use only (RUO) launch of the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next-generation sequencing (NGS) solution will allow laboratories to increase sequencing throughput, make reliable variant identifications, and increase the sales of these products, resulting in increased revenue generation.
|
|
5.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific is a prominent supplier of laboratory equipment and reagents, including solutions for genetic testing and analysis. Their product offerings encompass a wide range of technologies, from PCR and next-generation sequencing to microarrays, enabling researchers and clinicians to perform genetic testing with accuracy and efficiency.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In December 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry, for 17.4 billion. This acquisition helped to generate more revenue and boosted the market growth.
|
Conclusion
In the rapidly evolving genetic testing market, companies such as Illumina, Inc., Cepheid, Fulgent Genetics, PerkinElmer Inc., and Thermo Fisher Scientific Inc. play pivotal roles in driving innovation and advancing genetic testing technologies. Their diverse portfolios of products and services cater to the increasing demand for personalized medicine, early disease detection, and precision healthcare interventions. With a focus on accuracy, efficiency, and scalability, these companies empower healthcare providers and researchers to harness the power of genetics for improved patient outcomes and enhanced understanding of human health and disease. As the genetic testing market continues to expand, these companies are poised to shape its trajectory and contribute to advancements in healthcare worldwide.
